Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 15;15(1):414.
doi: 10.1186/s13018-020-01941-x.

Atypical periprosthetic femoral fracture associated with long-term bisphosphonate therapy

Affiliations

Atypical periprosthetic femoral fracture associated with long-term bisphosphonate therapy

Dávid Dózsai et al. J Orthop Surg Res. .

Abstract

Background: Atypical femoral fracture is one of the many complications after the long-term use of bisphosphonates. The American Society for Bone and Mineral Research has officially excluded periprosthetic femoral fractures (PFFs) from the definition of atypical femoral fractures (AFFs). Several case reports found that PFFs can occur with characteristics similar to those of AFFs. The purpose of our study was to evaluate the proportion of atypical fractures among Vancouver type B1 fractures, and to determine the association between the long-term use of bisphosphonates and the occurrence of atypical periprosthetic femoral fractures (APFFs).

Methods: In this retrospective study, we reviewed 41 patients with Vancouver type B1 periprosthetic fractures between January 1, 2011 and December 31, 2018. We classified them into two groups, namely atypical and typical PFFs, based on the fracture morphology. We noted the proportion of atypical periprosthetic fractures among B1 fractures and identified risk factors.

Results: Among the 41 PFFs, 5 (13%) fractures were classified as atypical PFF based on the radiological characteristics. The longer duration of bisphosphonate use was probably the only independent risk factor that significantly increases the occurrence of APFF (p = 0.03, 0.08 (CI 0.008 - 0.16)). There were no significant differences in age, gender, body mass index, comorbidities, corticosteroid use, positioning of the femoral stem, the method of fixation (cemented or cementless) and time lapse from before the primary prosthesis implantation to the PFF in the development of atypical fracture type.

Conclusions: There seems to be a correlation between the long-term intake of bisphosphonates and the atypical periprosthetic fracture. Atypical femoral fracture can also occur in the periprosthetic form.

Trial registration: Study number: 22/2019-SZTE, http://www.klinikaikutatas.hu/hu/kutatasetika/jovahagyott-vizsgalatok-koezerdeku-adatai/category/25-jovahagyott-vizsgalatok-kozerdeku-adatai-rkeb-2019.html?download=985:22-2019 .

Keywords: Atypical femoral fracture; Atypical periprosthetic femoral fracture; Bisphosphonate; Periprosthetic fracture.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
A 68-year-old patient with an atypical femoral fracture after a low energy fall
Fig. 2
Fig. 2
a 76-year-old female patient with an atypical periprosthetic femoral fracture, who took bisphofonates for 11 years. b Postoperative x-ray of the atypical fracture (operative fixation method with an 18 hole locking compression plate and 2 pieces of attachment). c X-ray of a healed atypical fracture after 1 year

Similar articles

Cited by

References

    1. Szathmári M. Evaluation of fracture risk in osteoporosis. Orv Hetil. 2011;152:1304–1311. doi: 10.1556/oh.2011.29191. - DOI - PubMed
    1. Adams AL, Adams JL, Raebel MA, et al. Bisphosphonate Drug Holiday and Fracture Risk: A Population-Based Cohort Study. J Bone Miner Res. 2018;33:1252–1259. doi: 10.1002/jbmr.3420. - DOI - PubMed
    1. Cremers S, Drake MT, Ebetino FH, et al. Pharmacology of bisphosphonates. Br J Clin Pharmacol. 2019;85:1052–1062. doi: 10.1111/bcp.13867. - DOI - PMC - PubMed
    1. Harvey NC, Curtis EM, Dennison EM, Cooper C. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 2018. The epidemiology of osteoporotic fractures; pp. 398–404.
    1. Reyes C, Hitz M, Prieto-Alhambra D, Abrahamsen B. Risks and Benefits of Bisphosphonate Therapies. J Cell Biochem. 2016;117:20–28. doi: 10.1002/jcb.25266. - DOI - PubMed

MeSH terms